Full metadata record
DC FieldValueLanguage
dc.contributor.authorTEILUF Ken_GB
dc.contributor.authorSEIDL C.en_GB
dc.contributor.authorBLECHERT B.en_GB
dc.contributor.authorGAERTNER F. C.en_GB
dc.contributor.authorGILBERTZ K.-P.en_GB
dc.contributor.authorFERNANDEZ Ven_GB
dc.contributor.authorBASSERMANN Fen_GB
dc.contributor.authorENDELL Jen_GB
dc.contributor.authorBOXHAMMER Ren_GB
dc.contributor.authorLECLAIR Stephaneen_GB
dc.contributor.authorVALLON M.en_GB
dc.contributor.authorAICHLER Men_GB
dc.contributor.authorFEUCHTINGER Aen_GB
dc.contributor.authorBRUCHERTSEIFER Franken_GB
dc.contributor.authorMORGENSTERN Alfreden_GB
dc.contributor.authorESSLER M.en_GB
dc.date.accessioned2015-07-14T00:09:08Z-
dc.date.available2015-07-13en_GB
dc.date.available2015-07-14T00:09:08Z-
dc.date.created2015-06-11en_GB
dc.date.issued2014en_GB
dc.date.submitted2014-12-08en_GB
dc.identifier.citationONCOTARGET vol. 6 no. 7 p. 4692 - 4703en_GB
dc.identifier.issn1949-2553en_GB
dc.identifier.uriwww.impactjournals.com/oncotargeten_GB
dc.identifier.urihttp://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=2986&path%5B%5D=5691en_GB
dc.identifier.urihttp://publications.jrc.ec.europa.eu/repository/handle/JRC93331-
dc.description.abstractIn spite of development of molecular therapeutics, multiple myeloma (MM) is fatal in most cases. CD38 is a promising target for selective treatment of MM. We tested radioimmunoconjugates consisting of the α-emitter 213Bi coupled to an anti-CD38 MAb in preclinical treatment of MM. Efficacy of 213Bi-anti-CD38-MAb was assayed towards different MM cell lines with regard to induction of DNA double-strand breaks, induction of apoptosis and initiation of cell cycle arrest. Moreover, mice bearing luciferase-expressing MM xenografts were treated with 213Bi-anti-CD38-MAb. Therapeutic efficacy was monitored by bioluminescence imaging, overall survival and histology. 213Bi-anti-CD38-MAb treatment induced DNA damage which did not result in activation of the G2 DNA-damage-response checkpoint, but instead in mitotic arrest and subsequent mitotic catastrophe. The anti-tumor effect of 213Bi-anti-CD38- MAb correlated with the expression level of CD38 in each MM cell line. In myeloma xenografts, treatment with 213Bi-anti-CD38-MAb suppressed tumor growth via induction of apoptosis in tumor tissue and significantly prolonged survival compared to controls. The major organ systems did not show any signs of 213Bi-induced toxicity. Preclinical treatment of MM with 213Bi-anti-CD38-MAb turned out as an effective therapeutic option.en_GB
dc.description.sponsorshipJRC.E.5-Nuclear chemistryen_GB
dc.format.mediumPrinteden_GB
dc.languageENGen_GB
dc.publisherIMPACT JOURNALS LLCen_GB
dc.relation.ispartofseriesJRC93331en_GB
dc.titleα-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myelomaen_GB
dc.typeArticles in periodicals and booksen_GB
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.